BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23240027)

  • 1. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
    Zhang S; Li G; Zhao Y; Liu G; Wang Y; Ma X; Li D; Wu Y; Lu J
    PLoS One; 2012; 7(12):e51461. PubMed ID: 23240027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
    Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP; Bonavida B
    Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
    Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
    Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
    BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.
    Raulf N; El-Attar R; Kulms D; Lecis D; Delia D; Walczak H; Papenfuss K; Odell E; Tavassoli M
    Br J Cancer; 2014 Nov; 111(10):1955-64. PubMed ID: 25314064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
    Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
    Fandy TE; Shankar S; Srivastava RK
    Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
    Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
    Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
    Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S
    Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity.
    Pan W; Luo Q; Yan X; Yuan L; Yi H; Zhang L; Li B; Zhang Y; Sun J; Qiu MZ; Yang DJ
    Biochem Pharmacol; 2018 Aug; 154():127-135. PubMed ID: 29679556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
    Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
    World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-expression of Smac promotes TRAIL-induced cell death in human hepatocellular carcinoma.
    Okano H; Shiraki K; Inoue H; Kawakita T; Saitou Y; Enokimura N; Yamamoto N; Sugimoto K; Fujikawa K; Murata K; Nakano T
    Int J Mol Med; 2003 Jul; 12(1):25-8. PubMed ID: 12792804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.
    Derakhshan A; Chen Z; Van Waes C
    Clin Cancer Res; 2017 Mar; 23(6):1379-1387. PubMed ID: 28039268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
    Bai L; McEachern D; Yang CY; Lu J; Sun H; Wang S
    Cancer Res; 2012 Mar; 72(5):1229-38. PubMed ID: 22241084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
    Nguyen DM; Yeow WS; Ziauddin MF; Baras A; Tsai W; Reddy RM; Chua A; Cole GW; Schrump DS
    Cancer J; 2006; 12(4):257-73. PubMed ID: 16925970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.
    Guo F; Nimmanapalli R; Paranawithana S; Wittman S; Griffin D; Bali P; O'Bryan E; Fumero C; Wang HG; Bhalla K
    Blood; 2002 May; 99(9):3419-26. PubMed ID: 11964312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.